5 completed, 2 unknown, 1 active not recruiting, 1 terminated. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 5, Unknown 2, Active not recruiting 1, Terminated 1 |
Follow brodalumab: new trials by email Literature Review of brodalumab trials Research Report on brodalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight Brodalumab - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 385 | 2022-07-21 | 2026-04-24 |
| Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab Brodalumab, Placebo, Guselkumab - Plaque Psoriasis, Psoriasis Vulgaris | Phase 4 | Terminated | LEO Pharma | 113 | 2020-12-17 | 2025-03-14 |
| Brodalumab in Palmoplantar Psoriasis Brodalumab - Palmoplantar Psoriasis | Phase 4 | Unknown | First OC Dermatology | 10 | 2020-12-01 | 2020-11-16 |
| Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis Secukinumab, Ixekizumab, Brodalumab - Psoriasis, Psoriasis Vulgaris | Phase 4 | Completed | Radboud University Medical Center | 244 | 2020-08-20 | 2026-03-17 |
| An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects Brodalumab - Psoriasis | Phase 4 | Active not recruiting | Bausch Health Americas, Inc. | 2 | 2020-01-24 | 2025-09-16 |
| Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis Brodalumab, Placebos - Psoriasis | Phase 4 | Unknown | Aarhus University Hospital | 50 | 2018-09-15 | 2019-07-10 |
| A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Brodalumab, Fumaric acid esters - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 210 | 2017-11-03 | 2025-03-13 |
| Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies Brodalumab - Psoriasis | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 39 | 2017-10-31 | 2021-03-10 |
| A Phase 4 Clinical Study of Brodalumab Brodalumab 210mg SC - Psoriasis Vulgaris, Psoriatic Arthritis | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 138 | 2016-07-04 | 2019-12-09 |
Psoriasis (6) · Arthritis, Psoriatic (1) · Skin Diseases (1) · Skin Diseases, Papulosquamous (1)
LEO Pharma (3) · Aarhus University Hospital (1) · Bausch Health Americas, Inc. (1) · First OC Dermatology (1) · Icahn School of Medicine at Mount Sinai (1) · Kyowa Kirin Co., Ltd. (1) · Radboud University Medical Center (1)
Belgium (3) · Germany (3) · Netherlands (3) · Denmark (2) · France (2) · Greece (2) · Italy (2) · Spain (2) · United Kingdom (2) · United States (2) · Austria (1) · Czechia (1) · Hungary (1) · Japan (1) · Poland (1)
Elke de Jong, MD, PhD (1) · Mark Lebwohl, MD (1) · Varsha Bhatt (1)
PMID 34656148, PMID 38300408, PMID 42577288
2019 (2), 2016 (1), 2017 (1), 2023 (1)